The Food and Drug Administration is considering pulling its authorization of Pfizer’s COVID-19 vaccine for healthy children ...

Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Activist Starboard Value, one of the first investors to publicly push Salesforce to make changes three years ago, increased ...

Hedge fund Starboard reveals Q2 strategy shifts: new stakes in TripAdvisor & iShares Russell 2000 ETF, boosted Salesforce & Pfizer holdings, trimmed ...

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...

At the same time, more than half of the US-listed stocks covered by Morningstar that reported earnings as of Aug. 11 beat ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled ‘A Phase 3 Multi-Center, ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. The FLOTILLA Study, officially titled ‘ENCORAFENIB/BINIMETINIB MASTER ...

These three dividend stocks are trading on the cheap given their true valuations. They should be on income investors' radars.

Dividend stocks are a time-tested way to retire or protect your portfolio if you are already retired. Their yield can give ...

Pfizer Inc. just made headlines by acquiring a promising biotech firm. The strategic move aims to enhance Pfizer's portfolio ...

Pfizer climbed 5.16% to Rs 5,390.30 after posting a strong performance in the June quarter. Revenue from operations stood at Rs 603.05 crore, up 7.14% YoY from Rs 562.86 crore and 1.88% higher than Rs ...